Market OpportunityTELA Bio is expected to take market share in the $1.5B hernia mesh market, translating to growth and profitability.
Product DifferentiationOviTex's biocompatibility and safety features, strength and handling benefits, and its lower-cost profile versus biologic competitors, has potential to be a disruptive device in both the hernia repair and plastic reconstructive industries.
Product LaunchNew products in both PRS and Hernia are anticipated to contribute to growth reacceleration.